| scholarly article | Q13442814 |
| P50 | author | Daniel B Costa | Q55130362 |
| Gregory J Riely | Q96189970 | ||
| Keith D Wilner | Q99596859 | ||
| D Ross Camidge | Q114292043 | ||
| Benjamin J Solomon | Q114292105 | ||
| Alice T Shaw | Q114292108 | ||
| P2093 | author name string | Caicun Zhou | |
| Paulina Selaru | |||
| Lucio Crinò | |||
| Myung-Ju Ahn | |||
| Patrick Schnell | |||
| S Martin Shreeve | |||
| Anna Polli | |||
| Sai-Hong I Ou | |||
| Robin Wiltshire | |||
| P2860 | cites work | Global cancer statistics | Q22241238 |
| Molecular pathology of lung cancer: key to personalized medicine | Q27691299 | ||
| Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer | Q27851410 | ||
| Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma | Q27851421 | ||
| Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors | Q27851431 | ||
| Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. | Q27851438 | ||
| EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer | Q27851440 | ||
| Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer | Q27851588 | ||
| ROS1 rearrangements define a unique molecular class of lung cancers | Q27851700 | ||
| Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial | Q27851712 | ||
| CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study | Q27852261 | ||
| Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. | Q27852316 | ||
| Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. | Q27852806 | ||
| Ceritinib in ALK-rearranged non-small-cell lung cancer | Q27852989 | ||
| Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. | Q27853059 | ||
| New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 | ||
| Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR | Q29547545 | ||
| Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK | Q29615472 | ||
| Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population | Q33833942 | ||
| Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib | Q34393558 | ||
| ALK in lung cancer: past, present, and future | Q34402260 | ||
| ALK inhibitors in non-small cell lung cancer: crizotinib and beyond | Q34431889 | ||
| Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib | Q34566991 | ||
| Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. | Q36044531 | ||
| Crizotinib for the Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: A Success Story to Usher in the Second Decade of Molecular Targeted Therapy in Oncology | Q36405628 | ||
| Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer | Q36422709 | ||
| Pharmacokinetic considerations in the treatment of CNS tumours | Q36574934 | ||
| Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease | Q36660669 | ||
| The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non–Small Cell Lung Cancer with EGFR Mutations | Q36927984 | ||
| Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study | Q37606591 | ||
| High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer | Q37681047 | ||
| Treating ALK-positive lung cancer—early successes and future challenges | Q37999657 | ||
| Cell culture modeling of genotype-directed sensitivity to selective kinase inhibitors: targeting the anaplastic lymphoma kinase (ALK). | Q39839990 | ||
| Taking Aim at ALK Across the Blood–Brain Barrier | Q43813186 | ||
| EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. | Q46113744 | ||
| EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers | Q46827197 | ||
| CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. | Q54602410 | ||
| Precision Oncology: An Overview | Q61661587 | ||
| P433 | issue | 17 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | crizotinib | Q5186964 |
| lung cancer | Q47912 | ||
| P304 | page(s) | 1881-1888 | |
| P577 | publication date | 2015-01-26 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases | |
| P478 | volume | 33 |
| Q33865475 | A crowded, but still varied, space: brigatinib in anaplastic lymphoma kinase-rearranged non-small cell lung cancer |
| Q33679543 | A large, single-center, real-world study of clinicopathological characteristics and treatment in advanced ALK-positive non-small-cell lung cancer |
| Q48931930 | A patient with complex multiple genomic ALK alterations |
| Q52722993 | A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy |
| Q54978002 | A real-world study of treatment patterns and survival outcome in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer. |
| Q26769879 | ALK inhibitors in non-small cell lung cancer: the latest evidence and developments |
| Q55262467 | ALK inhibitors, resistance development, clinical trials. |
| Q52880860 | ALK inhibitors: plateauing systemic and intracranial activity? |
| Q42359754 | ALK on my mind: alectinib takes an early lead in managing intracranial disease in non-small cell lung cancer with ALK rearrangements |
| Q37518624 | ALK: a tyrosine kinase target for cancer therapy |
| Q42330754 | ASCEND-2: a canary in a coal mine for descending to second-line treatment for ALK-rearranged non-small cell lung cancer |
| Q39718035 | ASCENDing the anaplastic lymphoma kinase ladder: a tale of two C-nibs |
| Q38763108 | Achievements and future developments of ALK-TKIs in the management of CNS metastases from ALK-positive NSCLC. |
| Q46143489 | Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial |
| Q27853360 | Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial |
| Q39220897 | Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer. |
| Q92286653 | Adverse Events of Concurrent Radiotherapy and ALK Inhibitors for Brain Metastases of ALK-Rearranged Lung Adenocarcinoma |
| Q36550838 | Alectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Relapsing on Standard Dose Alectinib |
| Q64959585 | Alectinib and Brigatinib: New Second-Generation ALK Inhibitors for the Treatment of Non-Small Cell Lung Cancer. |
| Q41820718 | Alectinib for the management of ALK-positive non-small cell lung cancer brain metastases |
| Q27853299 | Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial |
| Q53803847 | Alectinib in crizotinib-resistant, ALK-positive NSCLC. |
| Q58802261 | Alectinib in the treatment of ALK-positive non-small cell lung cancer: an update on its properties, efficacy, safety and place in therapy |
| Q35007620 | Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib |
| Q52580435 | Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study |
| Q39669119 | Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series |
| Q42434572 | Alectinib-a new chapter in the management of ALK-positive lung cancer |
| Q38652927 | An update of ALK inhibitors in human clinical trials. |
| Q48179589 | An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer. |
| Q37567731 | Analysis of clinical characteristics and prognosis of patients with anaplastic lymphoma kinase-positive and surgically resected lung adenocarcinoma |
| Q37592115 | Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer |
| Q42007490 | Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib |
| Q92619272 | Anaplastic lymphoma kinase inhibitors in non-small cell lung cancer patients with brain metastases: a meta-analysis |
| Q92424812 | Application of radiomics signature captured from pretreatment thoracic CT to predict brain metastases in stage III/IV ALK-positive non-small cell lung cancer patients |
| Q88288284 | Ascending role of next-generation ALK inhibitors |
| Q90646795 | Assessment of Effectiveness and Safety of Osimertinib for Patients With Intracranial Metastatic Disease: A Systematic Review and Meta-analysis |
| Q57176317 | Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine |
| Q52814108 | Best Practices in Treatment Selection for Patients With Advanced NSCLC. |
| Q37021294 | Bilateral breast adenocarcinomas with EML4-ALK fusion in a patient with multiple metastases successfully treated with crizotinib: is lung the primary site? |
| Q52318443 | Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment |
| Q89725043 | Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer |
| Q58738654 | Brain metastases in ALK-positive NSCLC - time to adjust current treatment algorithms |
| Q55429658 | Brain metastases in non-small-cell lung cancer: are tyrosine kinase inhibitors and checkpoint inhibitors now viable options? |
| Q38913258 | Brain metastasis in lung cancer: Building a molecular and systems-level understanding to improve outcomes |
| Q64238209 | Brigatinib for -positive metastatic non-small-cell lung cancer: design, development and place in therapy |
| Q64256419 | Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer |
| Q54485628 | Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy. |
| Q38816270 | Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance |
| Q38378641 | Ceritinib in patients with advanced, crizotinib-treated, anaplastic lymphoma kinase-rearranged NSCLC: Japanese subset |
| Q39365371 | Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial |
| Q39248666 | Characteristics and outcomes of ALK+ non-small cell lung cancer patients in Korea |
| Q47212151 | Characterization of Tumor Cells Using a Medical Wire for Capturing Circulating Tumor Cells: A 3D Approach Based on Immunofluorescence and DNA FISH. |
| Q47147655 | Characterization of distinct types of KRAS mutation and its impact on first-line platinum-based chemotherapy in Chinese patients with advanced non-small cell lung cancer |
| Q38741789 | Checkpoint inhibitors in the treatment of brain metastases of non-small-cell lung cancer and melanoma |
| Q90731627 | Chinese perspectives on clinical efficacy and safety of alectinib in patients with ALK-positive advanced non-small cell lung cancer |
| Q40835693 | Clinical Efficacy of Crizotinib in Treatment of Patients with Advanced NSCLC |
| Q89145785 | Clinical Pharmacokinetics of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer |
| Q38828319 | Clinical benefit of continuing crizotinib therapy after initial disease progression in Chinese patients with advanced ALK-rearranged non-small-cell lung cancer |
| Q31141961 | Clinical data from the real world: efficacy of Crizotinib in Chinese patients with advanced ALK-rearranged non-small cell lung cancer and brain metastases |
| Q64055605 | Clinical development of targeted and immune based anti-cancer therapies |
| Q35909271 | Clinical efficacy of crizotinib in Chinese patients with ALK-positive non-small-cell lung cancer with brain metastases |
| Q89295216 | Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer |
| Q47205132 | Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. |
| Q40961832 | Clinicopathologic Features of NSCLC Diagnosed During Pregnancy or the Peripartum Period in the Era of Molecular Genotyping |
| Q38844399 | Combination of Radiotherapy and Targeted Agents in Brain Metastasis: An Update |
| Q48387968 | Comparing pre-operative stereotactic radiosurgery (SRS) to post-operative whole brain radiation therapy (WBRT) for resectable brain metastases: a multi-institutional analysis |
| Q98613560 | Complete response in anaplastic lymphoma kinase-rearranged oncocytic thyroid cancer: A case report and review of literature |
| Q51037196 | Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma. |
| Q52682138 | Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer |
| Q26778500 | Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer |
| Q26738381 | Crizotinib resistance: implications for therapeutic strategies |
| Q26738385 | Crizotinib: from discovery to accelerated development to front-line treatment |
| Q46080398 | Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC. |
| Q38816700 | Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice. |
| Q42369337 | Current evidence in support of the second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor alectinib for the treatment of non-small cell lung cancer positive for ALK translocation |
| Q54980901 | Cystic brain metastases in ALK-rearranged non-small cell lung cancer. |
| Q36114660 | De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers |
| Q37402096 | Detection of ALK translocation in non-small cell lung carcinoma (NSCLC) and its clinicopathological significance using the Ventana immunohistochemical staining method: a single-center large-scale investigation of 1, 504 Chinese Han patients |
| Q39027385 | Diagnosis and Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer |
| Q39229266 | Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). |
| Q37003600 | Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation |
| Q50043843 | Drug resistance in HER2-positive breast cancer brain metastases: blame the barrier or the brain? |
| Q98771214 | Durable Complete Response to Alectinib in a Lung Adenocarcinoma Patient With Brain Metastases and Low-Abundance EML4-ALK Variant in Liquid Biopsy: A Case Report |
| Q37534932 | EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer |
| Q41670903 | EML4-ALK Variants: Biological and Molecular Properties, and the Implications for Patients |
| Q42369295 | Editorial on the article entitled "brigatinib efficacy and safety in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer in a phase I/II trial" |
| Q59128276 | Editorial: Central Nervous System Metastases in Lung Cancer Patients: From Prevention to Diagnosis and Treatment |
| Q55017122 | Effect of Food and Esomeprazole on the Pharmacokinetics of Alectinib, a Highly Selective ALK Inhibitor, in Healthy Subjects. |
| Q37381391 | Effective treatment with icotinib in lung adenocarcinoma with EGFR and ALK co-alterations and brain metastasis |
| Q90568504 | Efficacy of ALK inhibitors on NSCLC brain metastases: A systematic review and pooled analysis of 21 studies |
| Q50045235 | Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer |
| Q38846823 | Efficacy of crizotinib in first-line treatment of adults with ALK-positive advanced NSCLC. |
| Q90354160 | Elevated levels of pre-treatment lactate dehydrogenase are an unfavorable predictor factor in patients with EML4-ALK rearrangement non-small cell lung cancer treated with crizotinib |
| Q88497994 | Emerging Gene Fusion Drivers in Primary and Metastatic Central Nervous System Malignancies: A Review of Available Evidence for Systemic Targeted Therapies |
| Q88598919 | Emerging Trends in the Management of Brain Metastases from Non-small Cell Lung Cancer |
| Q48013012 | Emerging treatment paradigms for brain metastasis in non-small-cell lung cancer: an overview of the current landscape and challenges ahead |
| Q52644150 | Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study. |
| Q91314779 | Epidermal Growth Factor Receptor Mutation Status Confers Survival Benefit in Patients with Non-Small-Cell Lung Cancer Undergoing Surgical Resection of Brain Metastases: A Retrospective Cohort Study |
| Q37589516 | Evolving Cancer Classification in the Era of Personalized Medicine: A Primer for Radiologists |
| Q37350770 | Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis. |
| Q64109747 | Favorable predictors for survival in advanced ALK-positive non-small cell lung cancer patients beyond crizotinib resistance |
| Q37566842 | First-line treatment of advanced ALK-positive non-small-cell lung cancer |
| Q28068643 | Focus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLC |
| Q64248736 | From Whole-Brain Radiotherapy to Immunotherapy: A Multidisciplinary Approach for Patients with Brain Metastases from NSCLC |
| Q42367836 | Genetic Characterization of Brain Metastases in the Era of Targeted Therapy. |
| Q94378988 | Highlights from the Literature |
| Q38791747 | Histopathologic diagnosis of brain metastases: current trends in management and future considerations |
| Q92684950 | How I treat ALK-positive non-small cell lung cancer |
| Q38830389 | How might treatment of ALK-positive non-small cell lung cancer change in the near future? |
| Q38829087 | Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine. |
| Q38819317 | Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: A population-based study |
| Q36322851 | Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary? |
| Q37060709 | Kinase inhibitor-responsive genotypes in EGFR mutated lung adenocarcinomas: moving past common point mutations or indels into uncommon kinase domain duplications and rearrangements |
| Q49887882 | Kinase-targeted cancer therapies: progress, challenges and future directions |
| Q47205122 | Leptomeningeal metastases in non-small-cell lung cancer |
| Q48231295 | Lessons to be Learned: The Molecular Basis of Kinase-Targeted Therapies and Drug Resistance in Non-Small Cell Lung Cancer. |
| Q42339666 | Long-lasting response to third-line crizotinib treatment in a patient with non-small cell lung cancer with brain metastases and poor performance status. |
| Q47599265 | Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial |
| Q58607887 | Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study |
| Q26784085 | Lung cancer diagnosis and staging in the minimally invasive age with increasing demands for tissue analysis |
| Q55342417 | Lung cancer in never smokers from the Princess Margaret Cancer Centre. |
| Q52087016 | Lung cancer-associated brain metastasis: Molecular mechanisms and therapeutic options. |
| Q38940816 | Lung cancer: current therapies and new targeted treatments |
| Q90947631 | Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI? |
| Q54977894 | Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy. |
| Q38653663 | Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches |
| Q54950354 | Mechanisms and Therapy for Cancer Metastasis to the Brain. |
| Q64245738 | Mining-Guided Machine Learning Analyses Revealed the Latest Trends in Neuro-Oncology |
| Q47777234 | Molecular and clinical features of second-generation anaplastic lymphoma kinase inhibitors: ceritinib |
| Q26769659 | Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs |
| Q38746336 | Monitoring for and Characterizing Crizotinib Progression: A Chart Review of ALK-Positive Non-Small Cell Lung Cancer Patients |
| Q47108604 | Moving more potent and less toxic options to the frontline in the management of advanced lung cancer |
| Q64277515 | NF-κB hijacking theranostic Pt(ll) complex in cancer therapy |
| Q38576015 | New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer |
| Q64326768 | New developments in brain metastases |
| Q92134597 | New generation anaplastic lymphoma kinase inhibitors |
| Q42318799 | New treatment options and challenges for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer with brain metastases |
| Q26746230 | New treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinib |
| Q38763104 | Non-small cell lung cancer (NSCLC) and central nervous system (CNS) metastases: role of tyrosine kinase inhibitors (TKIs) and evidence in favor or against their use with concurrent cranial radiotherapy |
| Q47139758 | Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come. |
| Q38809939 | Novel Treatment Strategies for Brain Metastases in Non-small-cell Lung Cancer. |
| Q92451443 | Oncogenic driver mutations in Swiss never smoker patients with lung adenocarcinoma and correlation with clinicopathologic characteristics and outcome |
| Q98612903 | Optimal Care for Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: A Review on the Role and Utility of ALK Inhibitors |
| Q64100099 | Optimal timing and clinical value of radiotherapy in advanced ALK-rearranged non-small cell lung cancer with or without baseline brain metastases: implications from pattern of failure analyses |
| Q39128273 | Optimizing treatment for patients with anaplastic lymphoma kinase-positive lung cancer |
| Q47426457 | Outcome appraisal of patients with limited brain metastases (BMs) from non small cell lung cancer (NSCLC) treated with different local therapeutic strategies: a single institute evaluation. |
| Q54116816 | Outcomes of ALK positive lung cancer patients treated with crizotinib or second-generation ALK inhibitor: a monoinstitutional experience. |
| Q38665438 | Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib. |
| Q26745427 | Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer |
| Q57069397 | Overexpression of GPR35 confers drug resistance in NSCLC cells by β-arrestin/Akt signaling |
| Q35858617 | PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models |
| Q36241808 | PROFILE 1014: lessons for the new era of lung cancer clinical research |
| Q33926135 | Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial |
| Q31121041 | Pemetrexed/cisplatin as first-line chemotherapy for advanced lung cancer with brain metastases: A case report and literature review |
| Q28071903 | Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice |
| Q50927730 | Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer |
| Q38384492 | Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer |
| Q38688150 | Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer. |
| Q52718657 | Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib |
| Q64113475 | Prophylactic Cranial Irradiation vs Observation in Patients With Locally Advanced Non-Small Cell Lung Cancer: A Long-term Update of the NRG Oncology/RTOG 0214 Phase 3 Randomized Clinical Trial |
| Q48216924 | Pulsatile crizotinib treatment for brain metastasis in a patient with non-small-cell lung cancer |
| Q55189638 | Rapidly changing treatment algorithms for metastatic nonsquamous non-small-cell lung cancer. |
| Q37017020 | Re-Evaluating Progression in an Era of Progress: A Review of First- and Second-Line Treatment Options in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer |
| Q47875808 | Reactive Astrocytes in Brain Metastasis |
| Q99711973 | Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients |
| Q52673089 | Real-world outcomes in patients with ALK-positive non-small cell lung cancer treated with crizotinib |
| Q38473472 | Refining the treatment of NSCLC according to histological and molecular subtypes |
| Q41634338 | Resistances to targeted therapies and strategy for following therapeutic lines in metastatic NSCLC |
| Q93110791 | Response to Selective RET Inhibition With LOXO-292 in a Patient With RET Fusion-Positive Lung Cancer With Leptomeningeal Metastases |
| Q49888052 | Role and targeting of anaplastic lymphoma kinase in cancer |
| Q38630725 | Safety and efficacy of targeted agents monotherapy in advanced NSCLC. |
| Q38748356 | Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer |
| Q48419474 | Screening for ALK abnormalities in central nervous system metastases of non-small-cell lung cancer |
| Q28072496 | Second- and third-generation ALK inhibitors for non-small cell lung cancer |
| Q42344252 | Sequencing ALK inhibitors: alectinib in crizotinib-resistant patients, a phase 2 trial by Shaw et al. |
| Q39177404 | Sequencing brain metastases and opportunities for targeted therapies |
| Q38769610 | Sequencing of ALK Inhibitors in ALK+ Non-Small Cell Lung Cancer |
| Q38663460 | Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy |
| Q57168071 | Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date |
| Q30252216 | Stereotactic radiosurgery for small brain metastases and implications regarding management with systemic therapy alone |
| Q64238220 | Systematic review of sequencing of ALK inhibitors in -positive non-small-cell lung cancer |
| Q54978262 | Systemic Therapy of Lung Cancer CNS Metastases Using Molecularly Targeted Agents and Immune Checkpoint Inhibitors. |
| Q38738053 | Systemic therapies in the treatment of non-small-cell lung cancer brain metastases |
| Q92255269 | Systemic therapy for brain metastases |
| Q41428337 | Systemic therapy for echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase non-small cell lung cancer brain metastases. |
| Q30239901 | Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma |
| Q91845628 | TP53 mutations are predictive and prognostic when co-occurring with ALK rearrangements in lung cancer |
| Q26740329 | Tackling ALK in non-small cell lung cancer: the role of novel inhibitors |
| Q38715328 | Targeted Therapies for the Treatment of Brain Metastases in Solid Tumors |
| Q39192200 | Targeted Treatment of Brain Metastases |
| Q50052820 | Targeted drugs for systemic therapy of lung cancer with brain metastases |
| Q49956245 | Targeted therapy of brain metastases: latest evidence and clinical implications |
| Q64067749 | Targeting Molecular Pathways in Intracranial Metastatic Disease |
| Q38598523 | Targeting brain metastases in ALK-rearranged non-small-cell lung cancer. |
| Q38635259 | The Current Landscape of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer: Emerging Treatment Paradigms and Future Directions |
| Q37737536 | The Emerging Role of Targeted Therapy and Immunotherapy in the Management of Brain Metastases in Non-Small Cell Lung Cancer |
| Q38884328 | The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib. |
| Q38388307 | The efficacy of crizotinib in patients with ALK-positive nonsmall cell lung cancer. |
| Q55342455 | The emerging treatment landscape of advanced non-small cell lung cancer. |
| Q91709281 | The impact of systemic precision medicine and immunotherapy treatments on brain metastases |
| Q89497176 | The optional approach of oncogene-addicted non-small cell lung cancer with brain metastases in the new generation targeted therapies era |
| Q48512265 | The role of brigatinib in crizotinib-resistant non-small cell lung cancer. |
| Q56895374 | Therapeutic antibodies in cancer therapy |
| Q38484053 | Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine. |
| Q54967334 | Treating ALK-positive non-small cell lung cancer. |
| Q26795555 | Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy |
| Q90132769 | Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer |
| Q38739807 | Treatment modalities for advanced ALK-rearranged non-small-cell lung cancer |
| Q38528130 | Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions |
| Q38631019 | Treatment of ALK-rearranged non-small cell lung cancer: A review of the landscape and approach to emerging patterns of treatment resistance in the Australian context |
| Q61810591 | Treatment of advanced nonsmall cell lung cancer: First line, maintenance and second line - Indian consensus statement update |
| Q90688022 | Tyrosine Kinase Inhibitor Therapy for Brain Metastases in Non-Small-Cell Lung Cancer: A Primer for Radiologists |
| Q38887451 | Updates in the management of brain metastases. |
| Q47899183 | Whole-Brain Radiotherapy for Brain Metastases: Evolution or Revolution? |
| Q88682201 | Xenograft tumors derived from malignant pleural effusion of the patients with non-small-cell lung cancer as models to explore drug resistance |
Search more.